Deletion of CR1 is consistent with the lower mRNA expression level of this receptor in SALS patients, providing support for aberrant complement regulation as a part of ALS process and highlighting the potential use of complement molecules as disease biomarkers35,36. The gene discussed is CR1; the disease is amyotrophic lateral sclerosis.